Dynamics of Tumor-Infiltrating Lymphocytes as Indicators of Neoadjuvant Therapy Response in Luminal Breast Cancer - Takeaways - MDSpire

Dynamics of Tumor-Infiltrating Lymphocytes as Indicators of Neoadjuvant Therapy Response in Luminal Breast Cancer

  • By

  • Esma Uguztemur

  • Merve Dogan

  • February 27, 2026

  • 0 min

Share

  • 1

    Tumor-infiltrating lymphocytes (TILs) are crucial for assessing immune response in breast cancer, particularly in HR+/HER2− subtypes.

  • 2

    Neoadjuvant chemotherapy is increasingly used in high-risk HR+/HER2− breast cancer to assess treatment response and facilitate surgical downstaging.

  • 3

    Dynamic changes in TIL levels during therapy (delta-TIL) may provide insights into treatment response and tumor-immune interactions.

  • 4

    The study aimed to evaluate the association of baseline TIL levels and delta-TIL with pathological complete response and progression-free survival.

  • 5

    A total of 87 patients were included, predominantly preor perimenopausal, with invasive ductal carcinoma being the most common histology.

Original Source(s)

Dynamics of Tumor-Infiltrating Lymphocytes as Indicators of Neoadjuvant Therapy Response in Luminal Breast Cancer

  • by Esma Uguztemur, Merve Dogan

  • February 27, 2026

Related Content

This Week’s Biopharma News: New Approvals, Appeals, and AI

Datroway and Hepcludex secure notable FDA approvals, while Outlook wins its bevacizumab appeal, BioMarin reports phase 3 VOXZOGO data, and BMS partners with Anthropic

  • June 2, 2026

  • 5 min
Automated bone marrow cell classification using ensemble learning: performance, generalization, and clinical interpretability

Case Report: Intramedullary solitary fibrous tumor at the C7-T1 level diagnosed by STAT6 and treated with maximal safe resection